Why Is ACADIA PHARMACEUTICA (ACAD) Stock Down Today?
By the Top Tier Newswire AI Desk · September 25, 2026 at 11:58 AM ET · reviewed against 31 wire stories
ACADIA PHARMACEUTICA (ACAD) is down -5.70% in the latest session. Our newswire has captured 31 stories on ACAD across 11 sources in the last 36 hours, with AI sentiment reading bearish (avg 40/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
ACAD stock closed down 5.70% at $20.92 on Friday, marking one of the largest moves in its recent trading pattern. The decline follows a series of analyst actions that reduced price targets in response to updated trial data for remlifanserin. Analysts at multiple firms have revised their expectations downward, contributing to a broader reassessment of the stock’s near-term potential.
What Happened
Analysts from H.C. Wainwright, Needham, Deutsche Bank, BMO Capital, and Citizens all cut their price targets for ACAD in the past 36 hours. These moves followed the RADIANT trial update, which has prompted a reevaluation of the drug’s development timeline and commercial prospects. Despite some firms maintaining a Buy or Outperform rating, the downward revision in price targets has weighed on investor sentiment. The stock opened at $22.25 but quickly fell throughout the session, hitting an intraday low of $20.88 before closing near that level. The volume of 0.8 million shares was above the 3-month average, indicating increased attention to the stock.
What The Data Shows
ACAD has traded within a 52-week range of $19.69 to $30.96, and the stock has fallen 13.0% over the last eight sessions. The company has a market cap of $4.4 billion and a P/E ratio of 10.1, with revenue growing 11.8% in the trailing twelve months. Recent insider transactions include three sales totaling $1.3 million in the last 90 days. Unusual options activity was noted, with a call option print of $165,000. The stock also printed 32 fresh 52-week lows on September 25, indicating heightened bearish pressure.
What To Watch
The stock is set to continue under analyst scrutiny as more firms may adjust their outlooks. Investors should monitor coverage breadth and any further updates from Acadia on remlifanserin’s development.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
Acadia's latest trial update has put the spotlight on remlifanserin's development path, prompting analysts to reassess its near-term prospects and valuation.
49d agoThe FlyBEARISH 38Analyst
Acadia price target lowered to $33 from $37 at H.C. Wainwright
49d agoThe FlyBEARISH 34Analyst
Acadia Pharmaceuticals price target lowered to $35 from $41 at Needham
49d agoThe FlyBEARISH 34Analyst
Acadia Pharmaceuticals price target lowered to $31 from $38 at Deutsche Bank
Needham cuts Acadia Pharmaceuticals stock price target on trial results
Needham cuts Acadia Pharmaceuticals stock price target on trial results
49d agoThe FlyBEARISH 38Analyst
Acadia Pharmaceuticals price target lowered to $34 from $36 at BMO Capital
49d agoSeeking AlphaBULLISH 71General
Air Canada expects to buy back about C$800M in shares
Air Canada expects to buy back 27.59M shares for C$800M at C$29 via an oversubscribed issuer bid, reducing shares to 252.75M.
49d agoThe FlyBEARISH 38Analyst
Acadia Pharmaceuticals price target lowered to $33 from $36 at Citizens
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →